Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 06 tags : Phase 3 save search
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
Published: 2022-04-06 (Crawled : 22:00) - globenewswire.com
SPRO | $1.41 -4.08% -4.26% 380K
|
Health Technology
|
| O: 1.57%
H: 10.69%
C: 4.64%
therapeutics phase 3
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
Published: 2022-04-06 (Crawled : 21:00) - globenewswire.com
VAXX | News | $0.4761 2.43% 2.37% 290K
|
|
| O: 5.29%
H: 1.31%
C: -6.99%
ub-612 trial sars-cov-2 phase 3
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
Published: 2022-04-06 (Crawled : 19:00) - biospace.com/
AVDL | $17.33 -0.29% -0.29% 1.3M
|
Health Technology
|
| O: -0.9%
H: 2.87%
C: 1.06%
trial positive phase 3
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Published: 2022-04-06 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -2.1%
H: 3.71%
C: 2.34%
trials therapeutics presentation sclerosis phase 3
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission
Published: 2022-04-06 (Crawled : 11:00) - prnewswire.com
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 8.7%
H: 0.5%
C: -14.5%
treatment immunotherapy topline t-cell cancer submission e7777 ontak denileukin diftitox bla submission phase 3
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
Published: 2022-04-06 (Crawled : 01:00) - prnewswire.com
CALT | $17.65 -2.4% 4K
|
Health Technology
|
| O: 1.83%
H: 0.0%
C: -0.5%
topline chinese results phase 3 nefigard
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.